

## References

- Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. *Am J Ophthalmol*. 2004;137(3):486–495.
- Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. *Br J Ophthalmol*. 2001;85(10):1153–1157.
- Yasuda M, Kiyohara Y, Hata Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. *Ophthalmology*. 2009;116(11):2135–2140.
- Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. *Am J Ophthalmol*. 2007;144(1):15–22.
- de Jong PT. Age-related macular degeneration. *N Engl J Med*. 2006;355(14):1474–1485.
- Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005;308(5720):385–389.
- Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. *Science*. 2005;308(5720):419–421.
- Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. *Science*. 2005;308(5720):421–424.
- Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. *Nat Genet*. 2006;38(9):1055–1059.
- Li M, Atmaca-Sonmez P, Othman M, et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. *Nat Genet*. 2006;38(9):1049–1054.
- Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. *Nat Genet*. 2006;38(10):1173–1177.
- Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. *Science*. 2006;314(5801):989–992.
- Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. *Science*. 2006;314(5801):992–993.
- Fritsche LG, Loehhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. *Nat Genet*. 2008;40(7):892–896.
- Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2007;104(41):16227–16232.
- Spencer KL, Olson LM, Anderson BM, et al. C3 R102G polymorphism increases risk of age-related macular degeneration. *Hum Mol Genet*. 2008;17(12):1821–1824.
- Edwards AO, Fridley BL, James KM, Sharma AK, Cunningham JM, Tosakulwong N. Evaluation of clustering and genotype distribution for replication in genome wide association studies: the age-related eye disease study. *PLoS One*. 2008;3(11):e3813.
- Chen LJ, Liu DT, Tam PO, et al. Association of complement factor H polymorphisms with exudative age-related macular degeneration. *Mol Vis*. 2006;12:1536–1542.
- Mori K, Gehlbach PL, Kabasawa S, et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. *Invest Ophthalmol Vis Sci*. 2007;48(11):5315–5319.
- Wegscheider BJ, Weger M, Renner W, et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. *Ophthalmology*. 2007;114(4):738–742.
- Kim NR, Kang JH, Kwon OW, Lee SJ, Oh JH, Chin HS. Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans. *Invest Ophthalmol Vis Sci*. 2008;49(5):2071–2076.
- Ng TK, Chen LJ, Liu DT, et al. Multiple gene polymorphisms in the complement factor h gene are associated with exudative age-related macular degeneration in Chinese. *Invest Ophthalmol Vis Sci*. 2008;49(8):3312–3317.
- Lee KY, Vithana EN, Mathur R, et al. Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy. *Invest Ophthalmol Vis Sci*. 2008;49(6):2613–2619.
- Kondo N, Honda S, Kuno S, Negi A. Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy. *Ophthalmology*. 2009;116(2):304–310.
- Goto A, Akahori M, Okamoto H, et al. Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population. *J Ocul Biol Dis Infor*. 2009;2(4):164–175.
- Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. *Invest Ophthalmol Vis Sci*. 2010;51(11):5914–5919.
- Tanaka K, Nakayama T, Yuzawa M, et al. Analysis of candidate genes for age-related macular degeneration subtypes in the Japanese population. *Mol Vis*. 2011;17:2751–2758.
- Pei XT, Li XX, Bao YZ, et al. Association of c3 gene polymorphisms with neovascular age-related macular degeneration in a Chinese population. *Curr Eye Res*. 2009;34(8):615–622.
- Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. *Retina*. 2001;21(5):416–434.
- Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. *Am J Ophthalmol*. 1994;118(3):285–298.
- Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. *Retina*. 2008;28(2):201–211.
- Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. *Br J Ophthalmol*. 2007;91(9):1173–1176.
- Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G. Retinal angiomatous proliferation: natural history and progression of visual loss. *Retina*. 2009;29(6):732–739.
- Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. *Ophthalmology*. 2000;107(4):742–753.
- Kuroiwa S, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. *Retina*. 2003;23(3):417–420.
- Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. *Am J Ophthalmol*. 2004;138(6):1077–1079.
- Bottoni F, Massacesi A, Cigada M, Viola F, Musico I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. *Arch Ophthalmol*. 2005;123(12):1644–1650.
- Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. *Am J Ophthalmol*. 2005;139(5):917–918.
- Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. *Retina*. 2007;27(2):198–203.
- Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG. Chororetinal anastomosis and photodynamic therapy: a two-year follow-up study. *Gruefes Arch Clin Exp Ophthalmol*. 2007;245(8):1131–1139.
- Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB J*. 2000;14(7):835–846.

42. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. *Exp Eye Res.* 2001;73(6): 887–896.
43. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. *Ophthalmology.* 1991;98(7):1128–1134.
44. Cohen SY, Dubois L, Tadayoni R, Delahaye-Mazza C, Debibie C, Quentel G. Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. *Br J Ophthalmol.* 2007;91(3):354–359.
45. Ooto S, Ellabban AA, Ueda-Arakawa N, et al. Reduction of retinal sensitivity in eyes with reticular pseudodrusen. *Am J Ophthalmol.* 2013;156(6):1184–1191.
46. Querques G, Massamba N, Srour M, Boulanger E, Georges A, Souied EH. Impact of reticular pseudodrusen on macular function. *Retina.* July 9, 2013. [Epub ahead of print.]
47. Ueda-Arakawa N, Ooto S, Nakata I, et al. Prevalence and genomic association of reticular pseudodrusen in age-related macular degeneration. *Am J Ophthalmol.* 2013;155(2):260–269.
48. Lee MY, Yoon J, Ham DI. Clinical characteristics of reticular pseudodrusen in Korean patients. *Am J Ophthalmol.* 2012;153(3):530–535.

## Clinical Ophthalmology

### Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.



## Family (JU#0769-095JIKEI)




Figure 1. A consanguineous family (JU#0769–095JIKEI) with Alström syndrome. Two affected brothers (II-1 and II-2) with Alström syndrome and their unaffected parents are depicted.

show progressive retinal degeneration, with 90% becoming totally blind by the age of 16 years [19] and all becoming blind eventually [14,19]. Due to severe retinal degeneration and visual impairment during the first months of life, AS is often confused with congenital retinal degenerations, such as Leber congenital amaurosis (LCA) and congenital achromatopsia (ACHM) [20,21]. There are several reports of Japanese patients with AS [22–24]; however, there has been no report identifying any *ALMS1* mutation associated with AS in the Japanese population.

Recently, the development of next-generation sequencing technology has facilitated biologic and biochemical research by enabling the broad analysis of genomes [25–28]. The whole genome of an individual can now be sequenced at great depth, and genomic capture technology can be used to isolate sequences of interest [29–32].

Here, we used whole-exome sequencing to identify a novel *ALMS1* mutation in two Japanese brothers with AS. We also examined the clinical features of the two brothers in detail.

## METHODS

The protocol of this study was approved by the Institutional Review Board of the Jikei University School of Medicine and National Hospital Organization Tokyo Medical Center. The protocol adhered to the tenets of the Declaration of Helsinki, and written informed consent was obtained from all participants.

*Clinical studies:* The study was conducted in one consanguineous Japanese family (JU#0769–095JIKEI) with AS (Figure 1). The parents were second cousins. The clinical history was taken in detail, and the following ophthalmic examinations were performed: decimal best-corrected visual acuity (BCVA), slit-lamp and fundus examinations, and time-domain optical coherence tomography (TD-OCT; OCT3 Stratus; Carl Zeiss Meditec AG, Dublin, CA) or spectral-domain OCT (SD-OCT; Cirrus HD-OCT; Carl Zeiss Meditec AG). In color-vision tests, we used the Ishihara test (38-plate edition) and the Farnsworth Panel D-15 (Panel D-15). Visual-field testing by kinetic perimetry was conducted by using the Goldmann perimeter (GP; Haag Streit, Bern, Switzerland). Full-field electroretinography (ERG) was performed according to the protocols of the International Society for





Figure 2. Full-field electroretinogram. The electroretinograms (ERGs; patient II-1) at the age of 9 years, showing no standard combined, photopic, or 30-Hz flicker responses in either eye. The ERGs (patient II-2) at the age of 7 years, showing no rod, standard combined, photopic, or 30-Hz flicker responses in either eye.

Clinical Electrophysiology of Vision. The procedure and conditions for ERG recording have been detailed previously [33].

Fasting venous blood samples were analyzed for glucose, lipid, lipoprotein, and hemogram levels and renal, liver, and thyroid function tests. In addition, hemoglobin A<sub>1c</sub>, insulin, anti-thyroid peroxidase, anti-thyroglobulin antibodies, cortisol, luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, prolactin, parathyroid hormone, and thyroid receptor antibody levels were examined. Chest X-rays and electrocardiograms were also performed.

*DNA preparation and exome sequencing analysis:* We obtained venous blood samples from the affected brothers and their unaffected parents. Genomic DNA was extracted from the blood samples by using a Gentra Puregene Blood kit (Qiagen, Tokyo, Japan) and sheared with a Covaris Ultrasonicator (Covaris, Woburn, MA). Construction of paired-end sequence libraries and exome capture were performed by using the Agilent Bravo automated liquid-handling platform with SureSelect XT Human All Exon kit V4 + UTRs kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. Enriched libraries were sequenced by using in Illumina HiSeq2000 sequencer (San Diego, CA), according to the manufacturer's instructions for 100-bp paired-end sequencing. Reads were mapped to the reference human genome (1000 genomes phase 2 reference, hs37d5) with Burrows–Wheeler Aligner software version 0.6.2 [34]. Duplicated reads were then removed by Picard

MarkDuplicates module version 1.62, and mapped reads around insertion–deletion polymorphisms (INDELs) were realigned by using the Genome Analysis Toolkit (GATK) version 2.1–13 [35]. Base-quality scores were recalibrated by using GATK. Calling of mutations was performed by using the GATK UnifiedGenotyper module, and called single-nucleotide variants and INDELs were annotated by using snpEff software version 3.0 [36]. The mutations were annotated with the snpEff score (“HIGH,” “MODERATE,” or “LOW”) and with the allele frequency in the 1000 genomes database. The mutations were then filtered so that only those with “HIGH” or “MODERATE” snpEff scores (indicating that the amino acid sequence would be functionally affected) and a frequency of less than 1% in the 1000 genome database were analyzed further. We also used new variations, which were not found in the in-house database of seven people exome data with control individuals without ocular diseases. Mutations were classified by hereditary information into homozygous recessive, heterozygous recessive, and de novo mutations in the family members. Filtered mutations were scored with PolyPhen software version 2.2.2 [37], which predicts the effect on the structure and function of the protein. The above exome analysis pipeline is available at [Cell Innovation](#).








Figure 4. Fundus photographs of patients II-1 and II-2. **A** and **B**: Fundus photographs of patient II-1 at the age of 14 years (**A**) and patient II-2 at the age of 8 years (**B**) show retinal degeneration with attenuated vessels in the posterior poles of both eyes.

combined, photopic, or 30-Hz flicker responses in either eye (Figure 2). GP analysis at the age of 11 years showed markedly constricted visual fields in V-4e and I-4e isopters of both eyes (Figure 3A). The fundus photographs at the age of 14 years showed retinal degeneration with attenuated vessels from the arcade to the periphery in both eyes (Figure 4A). GP analysis at the age of 16 years showed more marked constricted visual fields of V-4e and I-4e isopters in both eyes than those observed at the age of 11 years (Figure 3B); a similar analysis at the age of 22 years showed a small visual field of V-4e isopter in the right eye and no visual field in the left eye (Figure 3C). TD-OCT at the age of 22 years showed total macular thinning in both eyes (Figure 5A). At the age of 29 years, his BCVA was light perception (LP) in the right eye and no light perception in the left eye. Intraocular pressure in each eye was within the normal range. He had severe cortical

and subcapsular cataracts in the right (Figure 6) and left eyes, and the fundi were not visible due to these cataracts.

*Ophthalmologic findings for patient II-2:* Patient II-2, the younger of the two brothers, visited our hospital at the age of 2 years and 6 months with the main complaint of poor visual acuity and photophobia. At the age of 3 years, his BCVA was 0.01 (+1.50 dpt) in the right eye and 0.01 (+1.50 dpt) in the left eye. Fundus examination showed retinal degeneration with slight attenuation of peripheral vessels. At the age of 4 years, he failed the Ishihara test. At the age of 6 years, the panel D-15 test showed irregular arrangements along no particular axis, and the GP could not be measured well because of low visual acuity and nystagmus. The ERG at the age of 7 years showed no rod, standard combined, photopic, or 30-Hz flicker responses in either eye (Figure 2). The fundus examination at






Figure 5. Optic coherence tomography findings. **A** and **B**: Time domain optic coherence tomography (OCT; retinal mapping) of patient II-1 at the age of 22 years (**A**) and II-2 at the age of 16 years (**B**) show total macular thinning in both eyes. **C**: Spectral-domain OCT (HD-5-line raster) of patient II-2 at the age of 23 years, showing marked macular thinning with indistinguishable retinal layers in the macular areas of both eyes.

the age of 8 years showed retinal degeneration with attenuated vessels from the arcade artery to the periphery in both eyes (Figure 4B). TD-OCT at the age of 16 years showed total macular thinning in both eyes (Figure 5B). At the age of 23 years, his BCVA was LP in both eyes, the intraocular

pressure was within the normal range in both eyes, posterior subcapsular cataracts were present in both eyes, and SD-OCT showed total macular thinning with indistinguishable retinal layers in both eyes (Figure 5C).



Figure 6. Anterior segment of the right eye in patient II-1. A severe cortical and anterior subcapsular cataract is present at the age of 29 years.

*Systemic features except ocular findings:* Systemic examinations were performed for patient II-1 at the age of 29 and patient II-2 at the age of 23. Both patients had hepatic dysfunction, hyperlipidemia, hypogonadism, short stature, and flat feet, and neither patient had hearing loss, renal failure, abnormal digits, history of developmental delay, mental retardation, scoliosis, hypertension, or alopecia. Obesity was present in patient II-1 only. Patient II-1 had T2DM, whereas patient II-2 showed hyperinsulinemia. Subclinical hypothyroidism was diagnosed in patient II-2 only. Recurrent pulmonary infections were not observed, and chest X-rays showed neither fibrotic infiltrations nor cardiac dilation in either patient. Infantile asthma was experienced by both patients. Electrocardiogram analysis showed no arrhythmia in either patient. Summaries of the clinical features, bio-information, and detailed laboratory data are presented in Table 1 and Table 2. Collectively, the phenotypes of the brothers were consistent with those described for AS.

*Exome sequencing analysis and identification of a gene mutation:* We performed whole-exome sequencing of the two affected brothers and their parents by using the Agilent Sure-Select Human All Exon kit followed by Illumina HiSeq 2000 platforms. Sequences of average length 11.8 Gb were generated from 101-bp paired-end sequences. After eliminating reads from PCR duplicates by discarding reads with duplicated start sites, we achieved 58-fold depth and 87% coverage in Refseq annotated regions (Table 3). When the sequences were compared with the reference human genome (hs37d5), 3,506,741 mutations were found in the two brothers and their

parents (Table 4). To distinguish potentially causal mutations from other mutations, we focused only on mutations that could change the amino acid sequence (19,574 mutations), such as nonsynonymous mutations, splice acceptor and donor site mutations, and INDELS. We also assumed the frequency of the mutations responsible for AS is likely to be under 1%. After filtering with snpEff score and frequency criteria, we filtered the remaining 3,685 mutations by using the pattern of inheritance and identified 17 gene mutations as causal candidates. Among these mutations, nine mutations were found homozygous in the HECT domain containing E3 ubiquitin protein ligase 3 (*HECTD3*), the vitrin (*VIT*), the protein kinase domain containing, cytoplasmic (*PKDCC*), the ATP-binding cassette, sub-family G (*WHITE*), member 8 (*ABCG8*), the leucine-rich pentatricopeptide repeat containing (*LRPPRC*), the G protein-coupled receptor 75 (*GPR75*), the notochord homeobox (*NOTO*), the matrix-remodelling associated 5 (*MXRA5*), and the *ALMS1* genes. Eight mutations were found as compound heterozygous mutations within the PERP, TP53 apoptosis effector (*PERP*), the transforming, acidic coiled-coil containing protein 2 (*TACC2*), the zinc finger protein, FOG family member 1 (*ZFPF1*), and the lipoxygenase homology domains 1 (*LOXHD1*) genes. No de novo mutations were found. To determine the causative gene, we investigated SAGE (*EyeSAGE*) database to determine if the candidate genes are expressed in the retina. Nine candidate mutations were identified within *VIT*, *LRPPRC*, *PERP*, *TACC2*, *ZFPF1*, and *ALMS1* genes. These nine candidate genes were further reduced by the *BIOBASE* Biologic Database and *RetNet* to determine which of the candidate genes would be likely to



TABLE 1. CLINICAL CHARACTERISTICS

Clinical findings	Patient II-1	Patient II-2	Percentage (%) in 182 cases <sup>a</sup>
Low vision	+	+	100
Subcapsular cataracts	+	+	32
Hearing loss	-	-	88
Cardiomyopathy	-	-	62
Type 2 diabetes mellitus	+	-	68
Childhood obesity	+	-	98
Hyperinsulinemia	-	+	92
Short stature	+	+	98
Hypertriglyceridemia	+	+	52
Hypothyroidism	-	+ (subclinical)	17
Hypogonadism	+	+	78
Elevated hepatic enzyme levels	+	+	92
Renal insufficiency	-	-	50
Renal hypertension	-	-	30
Pulmonary symptoms	-	-	52
Asthma	+ (childhood)	+ (childhood)	19
Muscle weakness	-	-	29
Global development delay	-	-	49
Wide feet	+	+	ND
Abnormal digits	-	-	ND
Scoliosis	-	-	ND
Alopecia	-	-	ND

ND, not described. <sup>a</sup>The cases are cited [13].

progress known phenotype with syndromic disorders. Finally, *ALMS1* was speculated to be the disease-causing gene. The *ALMS1* sequence was compared with the NCBI reference sequence of the *ALMS1* transcript (GenBank NM\_015120.4).

As a result, in the two affected brothers we identified a novel single-nucleotide substitution at position 6151 (c.6151C>T in exon 8) that causes a premature termination codon at amino acid 2051 (p.Q2051X) of the *ALMS1* gene resulting in a truncated protein. Both brothers were homozygous for the mutant allele, whereas the unaffected parents were heterozygous carriers of the allele, also reconfirmed by Sanger sequencing. The novel *ALMS1* mutation (p.Q2051X) was not found in any of 100 Japanese individuals without ocular disease in the [Single Nucleotide Polymorphism Database](#) or in the [Human Gene Mutation Database](#).

## DISCUSSION

To date, no patient with *ALMS1*-associated AS has been reported in the Japanese population. Here, we identified a novel *ALMS1* mutation (p.Q2051X) in two Japanese brothers with AS.

Marshall et al. advocate criteria for the diagnosis of AS [19]. In patients over the age of 15, it is necessary to fulfill “two major and two minor criteria” or “one major and four minor criteria” [19]. Our brother patients exhibited two major (*ALMS1* mutation and loss of vision, such as legal blindness) and more than four minor criteria (obesity, insulin resistance, and/or T2DM, hepatic dysfunction, short stature, and hypogonadism). Also, the phenotypic expression of AS is differentiated from BBS characterized by later onset retinal dystrophy, polydactyly, central obesity, learning disabilities, hypogonadism, and renal anomalies [38].

In patients with AS, phenotypic variability in disease severity and retinal function assessed by electroretinographic and visual-field testing [39] and variability in pathological

TABLE 2. BIO-INFORMATION AND BIOCHEMICAL ASSESSMENT

Bio-information and blood test results	Normal range	Patient II-1	Patient II-2
<b>Bio-information</b>			
Weight (kg)		60	52
Height (m)		1.52	1.55
Body mass index (kg/m <sup>2</sup> )	18.5–25	<b>25.96</b>	21.6
<b>Biochemical assessment</b>			
Fasting blood glucose (mg/dl)	65–109	<b>247</b>	77
Hemoglobin A1c (%)	4.6–6.2	<b>12.5</b>	6.0
Urea (mg/dl)	8–20	16	10
Creatinine (mg/dl)	0.50–1.10	0.99	0.63
Uric acid (mg/dl)	3.1–6.9	4.2	3.6
Sodium (mmol/l)	136–146	140	141
Potassium (mmol/l)	3.6–4.8	4.1	4.3
Chloride (mmol/l)	98–109	100	104
Calcium (mg/dl)	8.6–10.2	<b>10.3</b>	10.2
Aspartate aminotransferase (U/l)	10–33	<b>76</b>	<b>81</b>
Alanine aminotransferase (U/l)	6–35	<b>99</b>	<b>241</b>
Gamma glutamyl transpeptidase (U/l)	12–65	<b>134</b>	<b>135</b>
Alkaline phosphatase (U/l)	96–300	285	<b>319</b>
Low density lipoprotein-cholesterol (mg/dl)	70–139	120	<b>282</b>
Total cholesterol (mg/dl)	120–219	211	<b>441</b>
Triglycerides (mg/dl)	30–149	<b>309</b>	<b>761</b>
Albumin/globulin (g/dl)	3.5–5.2	5.0	5.1
<b>Hemogram</b>			
White blood cells (10 <sup>3</sup> /ml)	3.3–8.6	4.7	6.4
Red blood cells (10 <sup>6</sup> /ml)	4.10–5.50	5.00	4.88
Hemoglobin (g/dl)	13.5–16.5	14.0	14.3
Hematocrit (%)	40.0–50.0	42.3	42.7
Mean corpuscular volume (fl)	83.0–101.0	84.6	87.5
Platelets (10 <sup>3</sup> /ml)	150–350	166	251
Erythrocyte sedimentation rate (mm/h)	2–10	21	19
<b>Hormones and autoantibodies</b>			
Free T3 (pg/ml)	2.36–5.00	<b>2.34</b>	2.47
Free T4 (pmol/l)	0.88–1.67	1.33	<b>0.79</b>